Supplementary material to article by H-Y. Chiu et al. "Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis"

Table SI. Clinical characteristics of the 53 psoriasis patients studied

Cohort characteristics	
Age, years, mean \pm SD	46.7 ± 13.0
Gender (male/female)	34/19
Body weight, kg, mean ± SD	74.5 ± 15.8
Body length, cm, mean ± SD	165.7 ± 8.5
Duration of psoriasis, years, mean ± SD	12.4 ± 8.36
PASI at baseline	16.3 ± 9.2
Arthritis, n (%)	25/53 (47.2)
Previous biologics used, n , mean \pm SD	0.50 ± 0.72
Previous traditional antipsoriatic therapy used, n , mean \pm SD	2.08 ± 1.30
Duration of biologics treatment prior to AAA measurement, months, mean ± SD	21.2 ± 17.5
Anti-drug antibody, <i>n</i> (%)	27/53 (50.9)
Responder, <i>n</i> (%)	35/53 (66)

AAA: anti-adalimumab antibody; PASI: Psoriasis Area and Severity Index.